JCM
TXMD icon

Jafra Capital Management’s TherapeuticsMD TXMD Stock Holding History

Jafra Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$360K – 87
2017
Q1 		$360K Buy
+1,000
New +$309K 0.15% 60

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Jafra Capital Management's TXMD Position: Q2 2017 in Review

Jafra Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2017, closing a stake of 1,000 shares — an estimated $360K sold.

Jafra Capital Management first reported a position in TXMD in Q1 2017 and held it in 1 quarter. The position peaked at $360K in Q1 2017. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

  • Jafra Capital Management reported no remaining TherapeuticsMD position as of Q2 2017 after selling out during the quarter.
  • Jafra Capital Management sold 1,000 TherapeuticsMD shares in Q2 2017, an estimated $360K.
  • Jafra Capital Management first reported a position in TherapeuticsMD in Q1 2017 and held it in 1 quarter.
  • Jafra Capital Management's TherapeuticsMD position peaked at $360K in Q1 2017.
  • 117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on Jafra Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.